Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP.

Vibeke Miller BreinholtPer Holse MygindEva Dam ChristoffersenYing ZhangSho OtaR Will CharltonDorthe Viuff

Published in: British journal of clinical pharmacology (2022)

Safety and PD data from this phase 1 trial support that TransCon CNP is well tolerated, with a PK profile compatible with a once-weekly dosing regimen. Further studies are ongoing to evaluate the potential of TransCon CNP to positively impact abnormal endochondral ossification in children with achondroplasia.

Keyphrases

young adults
electronic health record
big data
randomized controlled trial
clinical trial
drug release
drug delivery